Exhibit 99.1


Forian Inc.
Announces Second Quarter 2025 Financial Results

Newtown, PA, August 13, 2025 (GLOBE NEWSWIRE) – Forian Inc. (Nasdaq: FORA), a leading provider of data science driven information and analytics solutions to the life science, healthcare and financial services industries, today announced results for the quarter ended June 30, 2025.

“Our strong second quarter results reflect continued execution and extend our track record of growth and operational discipline,” said Max Wygod, CEO and Executive Chairman of Forian. “We are successfully developing the business, expanding our core capabilities, and generating positive momentum in our markets. We remain focused on both organic and strategic investments that strengthen our platform and enhance the value we deliver across the healthcare ecosystem.”

Second Quarter 2025 Financial Results

Forian delivered the following results for the second quarter of 2025:
 
  
Three Months Ended
    Period-  
 
  
June 30,
    
over-
  
 
  
2025
    
2024
    
Period %
  
 
  
Unaudited
    
Unaudited
    
Change
  
Revenue
  
$
7,476,140
    
$
4,777,101
    
56%
 
 
                      
Net income (loss)
  
$
224,793
    
$
(2,553,259
)
  
109%
 
 
                      
Income (loss) per share - basic and diluted
  
$
0.01
    
$
(0.08
)
  
113%
 
 
                      
Adjusted EBITDA (a non-GAAP financial measure defined below)
  
$
591,073
    
$
78,202
    
656%
 

 
●
Revenue for the quarter was $7.5 million, a $2.7 million increase from $4.8 million in the prior year
 
●
Net income for the quarter was $0.2 million, or $0.01 per share, compared to a net loss of $2.6 million, or $0.08 per share, in the prior year
 
●
Adjusted EBITDA for the quarter was $0.6 million, compared to $0.1 million in the prior year
 
●
Cash, cash equivalents and marketable securities at June 30, 2025, totaled $35.6 million

Highlights

 
●
Revenue Growth: Continued to deliver strong quarterly revenue to date, reflecting acquisition impacts, strategic contract renewals and new wins
 
●
Strong Profitability: Realized operational efficiencies and the growth in our business model demonstrated ability drive profits and margin expansion
 
●
Signed Strategic Deals:  Executed agreements to strengthen our data assets and further enhance our offerings

Full Year 2025 Outlook

Based on information as of August 13, 2025, the Company is reconfirming the following outlook for the year ending December 31, 2025:

 
•
Revenue is expected to be in the range of $28 to $30 million; and
 
•
Adjusted EBITDA is expected to be in the range of ($1.0) to $1.0 million.

Non-GAAP Financial Measures

This release uses non-GAAP financial measures that are adjusted for the impact of various U.S. GAAP items. See the section titled “Non-GAAP Financial Measures” and the table entitled “Reconciliation of U.S. GAAP to Non-GAAP Financial Measures” below for details.

Quarterly Conference Call and Webcast

Forian will host a conference call and webcast at 4:30 p.m. ET on August 13, 2025 to discuss its financial results with the investment community. To register for the conference call, click here. The webcast will be available live at edge.media-server.com/mmc/p/76de8mny. This information is also available on our website at www.forian.com/investors. To be included on the Company’s email distribution list, please sign up at www.forian.com/investors.

About Forian

Forian provides a unique suite of data management capabilities and proprietary information and analytics solutions to optimize and measure operational, clinical and financial performance for customers within the traditional and emerging life sciences and healthcare payer and provider segments and, with its recent acquisition of Kyber Data Science, the financial services industry. Forian has industry leading expertise in acquiring, integrating, normalizing and commercializing large scale healthcare data assets. Forian’s information products overlay sophisticated data management and data science capabilities on top of a comprehensive clinical data lake to identify unique relationships, create distinctive information assets and generate proprietary insights. For more information, please visit the Company’s website at www.forian.com.

Cautionary Statements Regarding Forward-Looking Statements

This release contains “forward-looking statements” within the meaning of the federal securities laws, including Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). In this context, forward-looking statements often address expected future business and financial performance and financial condition, which may include GAAP and non-GAAP financial measures, and often contain words such as “expect,” “anticipate,” “intend,” “plan,” “believe,” “seek,” “see,” “will,” “would,” “target,” similar expressions and variations or negatives of these words. In particular, this release includes management’s outlook for 2025, which outlook is based on current estimates as of today’s date. Forward-looking statements by their nature address matters that involve risks and uncertainties, many of which are beyond our control and are not guarantees of future results, such as statements about future financial and operating results, company strategy and intended product offerings and market positioning and plans and estimates related to the restatement. These and other forward-looking statements are not guarantees of future results and are subject to risks, uncertainties and assumptions that could cause actual results to differ materially from those expressed in any forward-looking statements. Accordingly, there are or will be important factors that could cause actual results to differ materially from those indicated in such statements and, therefore, you should not place undue reliance on any such statements and caution must be exercised in relying on forward-looking statements. Factors that could cause actual results to differ include, but are not limited to, those risks and uncertainties associated with operations, strategy and goals, our ability to execute on our strategy, the outcome of the Company’s completion of the quantification and evaluation of the specific impact of the restatement, including the possibility of material adjustments thereto and the discovery of additional and unanticipated information during the procedures required to be completed before the Company is able to file its 2024 Form 10-K, and the additional risks and uncertainties set forth more fully under the caption “Risk Factors” in Forian’s Annual Report on Form 10-K for the year ended December 31, 2024, as filed with the SEC on April 11, 2025, and elsewhere in Forian’s filings and reports with the SEC.

Forward-looking statements contained in this release are made as of the date hereof, and we undertake no duty to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable law.

Media and Investor Contact:
forian.com/investors
ir@forian.com
267-225-6263
SOURCE: Forian Inc.

FORIAN INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(UNAUDITED)

 
  
June 30,
    
December 31,
  
 
  
2025
    
2024
  
 
  
(UNAUDITED)
        
ASSETS
            
Current assets:
            
Cash and cash equivalents
  
$
5,369,817
    
$
4,590,661
  
Marketable securities
    
30,279,208
      
30,492,088
  
Accounts receivable, net
    
5,267,632
      
3,971,702
  
Contract assets
    
2,666,627
      
2,586,712
  
Prepaid expenses
    
1,561,617
      
1,111,234
  
Other assets
    
1,396,202
      
1,707,694
  
Total current assets
    
46,541,103
      
44,460,091
  
 
                
Property and equipment, net
    
37,504
      
46,652
  
Intangible assets, net
    
1,097,741
      
1,192,044
  
Right of use assets, net
    
23,988
      
35,560
  
Deposits and other assets
    
762,301
      
1,435,496
  
Total assets
  
$
48,462,637
    
$
47,169,843
  
 
                
LIABILITIES AND STOCKHOLDERS’ EQUITY
                
Current liabilities:
                
Accounts payable
  
$
1,875,222
    
$
982,665
  
Accrued expenses
    
3,906,323
      
4,413,267
  
Short-term operating lease liabilities
    
23,988
      
23,423
  
Deferred revenues
    
4,911,427
      
4,487,686
  
Convertible notes payable, net of debt issuance costs ($6,000,000 in principal is held by a related party)
    
6,804,016
      
6,697,649
  
Total current liabilities
    
17,520,976
      
16,604,690
  
 
                
Long-term liabilities:
                
Other liabilities
    
-
      
512,137
  
Total long-term liabilities
    
-
      
512,137
  
Total liabilities
    
17,520,976
      
17,116,827
  
 
                
Commitments and contingencies Stockholders’ equity:
                
                 
Preferred Stock; par value $0.001; 5,000,000 Shares authorized; 0 issued and outstanding as of June 30, 2025 and December 31, 2024
    
-
      
-
  
Common Stock; par value $0.001; 95,000,000 Shares authorized; 31,202,312 issued and outstanding as of  June 30, 2025 and 31,010,788 issued and outstanding as of December 31, 2024
    
31,203
      
31,011
  
Additional paid-in capital
    
81,726,637
      
79,937,115
  
Accumulated deficit
    
(50,816,179
)
    
(49,915,110
)
Total stockholders’ equity
    
30,941,661
      
30,053,016
  
Total liabilities and stockholders’ equity
  
$
48,462,637
    
$
47,169,843
  

FORIAN INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(UNAUDITED)

 
  
For the Three Months Ended
June 30,
    
For the Six Months Ended
June 30,
  
 
  
2025
    
2024
    
2025
    
2024
  
Revenue
  
$
7,476,140
    
$
4,777,101
    
$
14,532,256
    
$
9,654,479
  
 
                                
Costs and Expenses:
                                
Cost of revenue
    
3,228,169
      
1,806,918
      
6,359,791
      
3,510,275
  
Research and development
    
675,731
      
307,201
      
1,281,968
      
697,090
  
Sales and marketing
    
1,495,710
      
1,017,659
      
2,878,437
      
2,072,800
  
General and administrative
    
1,971,959
      
3,229,757
      
5,251,053
      
6,513,246
  
Litigation settlements and related expenses
    
-
      
942,311
      
-
      
1,151,276
  
Strategic review and transaction related expenses
    
6,145
      
435,844
      
6,145
      
435,844
  
Depreciation and amortization
    
52,350
      
7,889
      
103,451
      
16,776
  
Total costs and expenses
    
7,430,064
      
7,747,579
      
15,880,845
      
14,397,307
  
 
                                
Operating income (loss)
    
46,076
      
(2,970,478
)
    
(1,348,589
)
    
(4,742,828
)
 
                                
Other Income (Expense):
                                
Change in fair value of warrant liability
    
-
      
430
      
-
      
543
  
Interest and investment income
    
347,968
      
618,316
      
676,816
      
1,293,473
  
Gain on sale of investment
    
-
      
-
      
-
      
48,612
  
Interest expense
    
(53,689
)
    
(193,306
)
    
(106,367
)
    
(392,269
)
Gain on debt redemption
    
-
      
-
      
-
      
137,356
  
Total other income, net
    
294,279
      
425,440
      
570,449
      
1,087,715
  
 
                                
Income (loss) from continuing operations before income taxes
    
340,355
      
(2,545,038
)
    
(778,140
)
    
(3,655,113
)
Income taxes
    
(115,562
)
    
(8,221
)
    
(122,929
)
    
(110,761
)
Net income (loss)
  
$
224,793
    
$
(2,553,259
)
  
$
(901,069
)
  
$
(3,765,874
)
 
                                
Basic net income (loss) per common share
  
$
0.01
    
$
(0.08
)
  
$
(0.03
)
  
$
(0.12
)
Diluted net income (loss) per common share
  
$
0.01
    
$
(0.08
)
  
$
(0.03
)
  
$
(0.12
)
Weighted-average shares outstanding - basic
    
31,202,312
      
31,098,497
      
31,163,137
      
31,049,647
  
Weighted-average shares outstanding - diluted
    
31,293,644
      
31,098,497
      
31,163,137
      
31,049,647
  

FORIAN INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(UNAUDITED)

 
  
For the Period Ended June 30,
  
 
  
2025
    
2024
  
CASH FLOWS FROM OPERATING ACTIVITIES:
            
Net loss
  
$
(901,069
)
  
$
(3,765,874
)
Adjustments to reconcile net loss to net cash provided by (used in) operating activities - continuing operations:
                
Depreciation and amortization
    
103,451
      
16,776
  
Amortization on right of use asset
    
11,572
      
10,664
  
Amortization of debt issuance costs
    
2,666
      
2,667
  
Accrued interest on convertible Notes
    
103,701
      
389,602
  
Amortization of discount - proceeds from sale of discontinued operations
    
-
      
(20,712
)
Accretion of discount - marketable securities
    
(627,201
)
    
(1,237,337
)
Gain on sale of investment
    
-
      
(48,612
)
Gain on debt redemption
    
-
      
(137,356
)
Provision for credit losses
    
-
      
168,750
  
Stock-based compensation expense
    
1,954,288
      
3,321,551
  
Change in fair value of warrant liability
    
-
      
(543
)
Change in operating assets and liabilities:
                
Accounts receivable
    
(1,295,930
)
    
(1,266,187
)
Contract assets
    
(79,915
)
    
171,358
  
Prepaid expenses
    
(450,383
)
    
61,248
  
Changes in lease liabilities during the period
    
(11,572
)
    
(21,624
)
Deposits and other assets
    
984,687
      
(572,153
)
Accounts payable
    
892,557
      
1,328,176
  
Accrued expenses
    
(506,944
)
    
(931,686
)
Deferred revenues
    
423,741
      
789,152
  
Other liabilities
    
(500,000
)
    
(489,040
)
Net cash provided by (used in) operating activities
    
103,649
      
(2,231,180
)
 
                
CASH FLOWS FROM INVESTING ACTIVITIES:
                
Purchase of marketable securities
    
(50,635,919
)
    
(87,732,380
)
Sale of marketable securities
    
51,476,000
      
85,255,076
  
Proceeds from sale of investment
    
-
      
48,612
  
Cash from sale of discontinued operations
    
-
      
1,666,666
  
Net cash provided by (used) investing activities
    
840,081
      
(762,026
)
 
                
CASH FLOWS FROM FINANCING ACTIVITIES:
                
Cash used to redeem convertible notes
    
-
      
(950,000
)
Repurchase of common stock
    
7,721
      
-
  
Tax payments related to shares withheld for vested restricted stock units
    
(172,295
)
    
(100,662
)
Net cash used in financing activities
    
(164,574
)
    
(1,050,662
)
 
                
Net change in cash
    
779,156
      
(4,043,868
)
 
                
Cash and cash equivalents, beginning of period
    
4,590,661
      
6,042,986
  
 
                
Cash and cash equivalents, end of period
  
$
5,369,817
    
$
1,999,118
  
 
                
Supplemental disclosure of cash flow information:
                
Cash for paid for taxes
   $ 163,428
    $ 48,492
 

Non-GAAP Financial Measures

In this press release, we have provided certain non-GAAP measures, which we define as financial information that has not been prepared in accordance with U.S. GAAP. The non-GAAP financial measure provided herein is earnings before interest, taxes, non-cash and other items (“Adjusted EBITDA”), which should be viewed as supplemental to, and not as an alternative for, net income or loss calculated in accordance with U.S. GAAP (referred to below as “net loss”).

Adjusted EBITDA is used by our management as an additional measure of our Company’s performance for purposes of business decision-making, including developing budgets, managing expenditures and evaluating potential acquisitions or divestitures. Period-to-period comparisons of Adjusted EBITDA help our management identify additional trends in our Company’s financial results that may not be shown solely by period-to-period comparisons of net income. In addition, we may use Adjusted EBITDA in the incentive compensation programs applicable to some of our employees in order to evaluate our Company’s performance. Our management recognizes that Adjusted EBITDA has inherent limitations because of the excluded items, particularly those items that are recurring in nature. In order to compensate for those limitations, management also reviews the specific items that are excluded from Adjusted EBITDA, but included in net income, as well as trends in those items.

We believe that the presentation of Adjusted EBITDA is useful to investors in their analysis of our results for reasons similar to the reasons why our management finds it useful and because it helps facilitate investor understanding of decisions made by management in light of the performance metrics used in making those decisions. In addition, as more fully described below, we believe that providing Adjusted EBITDA, together with a reconciliation of net loss to Adjusted EBITDA, helps investors make comparisons between our Company and other companies that may have different capital structures, different effective income tax rates and tax attributes, different capitalized asset values and/or different forms of employee compensation. However, Adjusted EBITDA is not intended as a substitute for comparisons based on net loss. In making any comparisons to other companies, investors need to be aware that companies use different non-GAAP measures to evaluate their financial performance. Investors should pay close attention to the specific definition being used and to the reconciliation between such measures and the corresponding U.S. GAAP measures provided by each company under applicable SEC rules.

The following is an explanation of the items excluded by us from Adjusted EBITDA but included in net loss:

 
•
Depreciation and Amortization. Depreciation and amortization expense is a non-cash expense relating to capital expenditures and intangible assets arising from acquisitions that are expensed on a straight-line basis over the estimated useful life of the related assets. The Company excludes depreciation and amortization expense from Adjusted EBITDA because management believes that (i) the amount of such expenses in any specific period may not directly correlate to the underlying performance of the business operations and (ii) such expenses can vary significantly between periods as a result of new acquisitions and full amortization of previously acquired tangible and intangible assets. Accordingly, management believes that this exclusion assists management and investors in making period-to-period comparisons of operating performance. Investors should note that the use of tangible and intangible assets contributed to revenue in the periods presented and will contribute to future revenue generation and should also note that such expense will recur in future periods.

 
•
Stock-Based Compensation Expense. Stock-based compensation expense is a non-cash expense arising from the grant of stock-based awards to employees. Management believes that excluding the effect of stock-based compensation from Adjusted EBITDA assists management and investors in making period-to-period comparisons in the Company’s operating performance because (i) the amount of such expenses in any specific period may not directly correlate to the underlying performance of business operations and (ii) such expenses can vary significantly between periods as a result of the timing of grants of new stock-based awards, including grants in connection with acquisitions. Management believes that excluding stock-based compensation from Adjusted EBITDA assists management and investors in making meaningful comparisons between the Company’s operating performance and the operating performance of other companies that may use different forms of employee compensation or different valuation methodologies for their stock-based compensation. Investors should note that stock-based compensation is a key incentive offered to employees whose efforts contributed to the operating results in the periods presented and are expected to contribute to operating results in future periods. Investors should also note that such expenses will recur in the future.

 
•
Interest Expense. Interest expense is associated with the convertible notes entered into on September 1, 2021 in the amount of $24,000,000 (the “Notes”). The Notes are due on September 1, 2025, and accrue interest at an annual rate of 3.5%. Management excludes interest expense from Adjusted EBITDA (i) because it is not directly attributable to the performance of business operations and, accordingly, its exclusion assists management and investors in making period-to-period comparisons of operating performance and (ii) to assist management and investors in making comparisons to companies with different capital structures. Investors should note that interest expense associated with the Notes will recur in future periods.

 
•
Interest and Investment Income. Interest and Investment income is associated with the level of marketable debt securities and other interest-bearing accounts in which the Company invests. Interest and investment income can vary over time due to changes in interest rates and level of investments. Management excludes interest and investment income from Adjusted EBITDA (i) because these items are not directly attributable to the performance of business operations and, accordingly, their exclusion assists management and investors in making period-to-period comparisons of operating performance and (ii) to assist management and investors in making comparisons to companies with different capital structures. Investors should note that interest and investment income will recur in future periods.

 
•
Other Items. The Company engages in other activities and transactions that can impact net loss. In the periods reported, these other items included (i) gain on sale of investment relating to the sale of a minority equity interest and (ii) gain on debt redemption which relates to a gain on the early retirement of a portion of the Notes. Management excludes these other items from Adjusted EBITDA because management believes these activities or transactions are not directly attributable to the performance of business operations and, accordingly, their exclusion assists management and investors in making period-to-period comparisons of operating performance. Investors should note that some of these other items may recur in future periods.

 
•
Litigation related expenses. Management excludes litigation expenses that are extraordinary in nature and are unrelated to the Company’s day-to-day business operations. The nature of these expenses is primarily related to direct and incremental third-party legal expenses and settlement expenses, net of any insurance recoveries, associated with such litigation, which pertains to entities acquired in the Helix merger.

 
•
Strategic review and acquisition related expenses. Management excludes certain professional expenses that are extraordinary in nature and are unrelated to the Company’s day-to-day business operations. The nature of these expenses is primarily related to a strategic review of the Company’s operations and acquisition of Kyber.

 
•
Contract termination impacts. Management excludes certain expenses that are extraordinary in nature and are unrelated to the Company’s day-to-day business operations. The nature of these expenses is primarily related to the impact of an adjustment related to the cancellation of an inbound information contract. On September 23, 2024, the Company was informed by one of its information vendors that it was exercising the right to terminate the agreement with the Company effective September 25, 2024, based on restrictions imposed by the supplier’s upstream licensor. As a result, the Company recorded an adjustment of $542,389, to reduce cost of revenues, during the year ended December 31, 2024, representing previously recorded charges under the contract that will not be paid. On July 2, 2025, the Company entered into a Termination and Wind Down Agreement with the vendor providing for a reduction of fees for the period through the termination date $175,000. As a result, the Company recorded an adjustment of $175,000 included in cost of revenues during the three months ended June 30, 2025, representing previously recorded charges under the contract that will not be paid.

 
•
Income tax (benefit) expense. Management excludes the income tax (benefit) expense from Adjusted EBITDA (i) because management believes that the income tax (benefit) expense is not directly attributable to the underlying performance of business operations and, accordingly, its exclusion assists management and investors in making period-to-period comparisons of operating performance and (ii) to assist management and investors in making comparisons to companies with different tax attributes.

There are limitations to using non-GAAP financial measures because non-GAAP financial measures are not prepared in accordance with U.S. GAAP and may be different from non-GAAP financial measures provided by other companies.

The non-GAAP financial measures are limited in value because they exclude certain items that may have a material impact upon our reported financial results. In addition, they are subject to inherent limitations as they reflect the exercise of judgments by management about which items are adjusted to calculate our non-GAAP financial measures. We compensate for these limitations by analyzing current and future results on a U.S. GAAP basis as well as a non-GAAP basis and also by providing U.S. GAAP measures in our public disclosures.

Non-GAAP financial measures should not be considered in isolation from, or as a substitute for, financial information prepared in accordance with U.S. GAAP. We encourage investors and others to review our financial information in its entirety, not to rely on any single financial measure to evaluate our business and to view our non-GAAP financial measures in conjunction with the most directly comparable U.S. GAAP financial measures.

The following table reconciles the specific items excluded from U.S. GAAP metrics in the calculation of non-GAAP metrics for the periods shown below:

FORIAN INC.
RECONCILIATION OF US GAAP TO NON-GAAP FINANCIAL MEASURES
(UNAUDITED)

   
For the Three Months Ended June 30,
    
For the Six Months Ended June 30,
  
   
2025
    
2024
    
2025
    
2024
  
Revenue
  
$
7,476,140
    
$
4,777,101
    
$
14,532,256
    
$
9,654,479
  
                                 
Net income (loss)
  
$
224,793
    
$
(2,553,259
)
  
$
(901,069
)
  
$
(3,765,874
)
                                 
Depreciation and amortization
    
52,350
      
7,889
      
103,451
      
16,776
  
Stock based compensation expense
    
661,502
      
1,662,636
      
1,954,288
      
3,321,551
  
Change in fair value of warrant liability
    
-
      
(430
)
    
-
      
(543
)
Interest and investment income
    
(347,968
)
    
(618,316
)
    
(676,816
)
    
(1,293,473
)
Interest expense
    
53,689
      
193,306
      
106,367
      
392,269
  
Gain on sale of investment
    
-
      
-
      
-
      
(48,612
)
Gain on debt redemption
    
-
      
-
      
-
      
(137,356
)
Litigation settlement and related expenses
    
-
      
942,311
      
-
      
1,151,276
  
Strategic review related expenses
    
6,145
      
435,844
      
6,145
      
435,844
  
Impact of contract termination
    
(175,000
)
    
-
      
(175,000
)
    
-
  
Income tax expense
    
115,562
      
8,221
      
122,929
      
110,761
  
                                 
Adjusted EBITDA
  
$
591,073
    
$
78,202
    
$
540,295
    
$
182,619